Adenosine kinase is a key determinant for the anti‐HCV activity of ribavirin
Kyoko Mori, Osamu Hiraoka, Masanori Ikeda, Yasuo Ariumi, Akiko Hiramoto, Yusuke Wataya, Nobuyuki Kato – 26 March 2013 – Ribavirin (RBV) is often used in conjunction with interferon‐based therapy for patients with chronic hepatitis C.